Highest-materiality recent filing
All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.
MetaVia stockholders approve reverse stock split (1:5–1:22) and 200,000-share equity plan increase
Stockholders approved reverse stock split at ratio in range 1-for-5 to 1-for-22; Board to determine final ratio.
DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.
MetaVia announces Phase 1 data: DA-1726 48 mg yields 9.1% weight loss at Day 54 without plateau
48 mg cohort achieved 9.1% mean body weight reduction at Day 54; no plateau through Week 8.
MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726
Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.
MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity
Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.
MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss
Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.
MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses
Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.
MetaVia closes $9.3M public offering with full over-allotment; net proceeds ~$7.7M for DA-1726
Closed offering of 3,005,574 shares/equivalents + 4,508,361 Series C and Series D Warrants at $3.10 each.
MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54
Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.
Reverse split at 1-for-11 ratio effective 5:00 p.m. ET Dec 4, 2025; begins split-adjusted trading Dec 5.
MetaVia Phase 2a vanoglipel shows HbA1c -0.54%p, ALT reductions in MASH trial
At Week 16, vanoglipel monotherapy reduced HbA1c by 0.54%p and combination therapy by 0.66%p from baseline 6.99% (p<0.05 vs placebo).
MetaVia reports Q3 net loss $3.4M, cash $14.3M; DA-1726 48mg cohort data due by year-end
Net loss of $3.4M ($0.14 per share) vs $5.7M ($0.55) in Q3 2024; cash $14.3M expected to fund into 2026.
MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025
Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.
MetaVia doses first patient in 48 mg MAD cohort of Phase 1 obesity trial; Q4 top-line data expected
First patient dosed in 48 mg multiple ascending dose cohort of DA-1726 (GLP1R/GCGR dual agonist) for obesity.
MetaVia shareholders approve reverse stock split and share issuance to Dong-A Socio
Elected Mark A. Glickman and Michael Salsbury as Class III directors until 2028.
MetaVia receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified MetaVia on May 29, 2025 that its closing bid price was below $1.00 for 30 consecutive business days.
MetaVia raises $10M in private placement; issues shares and pre-funded warrants at $0.71/unit
Gross proceeds ~$10M from 9.48M shares ($0.71/each) and 4.61M pre-funded warrants ($0.709/each).
MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1
Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.
MetaVia Phase 2a DA-1241 hits ALT reduction of 22.8 U/L, CAP score down 23 dB/m in MASH patients
DA-1241 100 mg lowered ALT by 22.8 U/L (p<0.05 vs placebo) after 16 weeks in patients with baseline ALT 40-200 U/L.
MetaVia reports dose-dependent weight loss and no CV effects in Phase 1 MAD study of DA-1726
Clear dose-dependent body weight reduction from 8 mg to 32 mg; BMI change significantly greater vs placebo.
Mean weight loss 4.3% (max 6.3%) at 32 mg dose on Day 26 (p=0.0005).
MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April
Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.
MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients
DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).
NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726
Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.
NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024
Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.
NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs
45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.
NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled
Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.
NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024
45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).
NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed
Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.
On March 1, 2024, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth, age 66, as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of March 1, 2024.
On November 1, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed James P. Tursi, M.D., effective immediately, to serve as a Class I director
On October 25, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of October 27, 2023.
On September 18, 2023, Ms. Na Yeon (Irene) Kim provided notice of her resignation from the Board of Directors (the “Board”) of NeuroBo Pharmaceuticals, Inc. (the “Company”), effective immediately.
appointed Mr. Hyung Heon Kim, a member of the Board, as the Company’s Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer effective as of August 11, 2023.
On May 11, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed Mark A. Glickman, effective immediately, to serve as a Class III director
On January 12, 2023, the Board appointed Joseph Hooker as the Company’s Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, effective as of January 12 , 2023.
On January 12, 2023, Gil Price, M.D. resigned as Chief Executive Officer and President of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), effective immediately.
appointed D. Gordon Strickland, effective immediately, to serve as a Class I director to hold office for a term expiring at the Company’s 2023 annual meeting
Andrew I. Koven, a current director of the Company was elected Chairman of the Board
Mr. Douglas J. Swirsky provided notice of his resignation from the Board of Directors
Richard Kang, Ph.D. resigned from his positions as Chief Executive Officer and President of the Company, effective as of November 3, 2021
Max materiality 0.85 · Median 0.60 · Most common event other_material